If you have been reading about Cyclic heptapeptide and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-01-10. Where a claim depends on a specific study, the study is described rather than over-claimed.
Bremelanotide is a synthetic cyclic heptapeptide developed under the research code PT-141. The code reflects its position in an internal compound series rather than a chemical classification, and the name bremelanotide was later adopted for regulatory filings. Structurally it belongs to the melanocortin peptide family and shares a core sequence motif with alpha-melanocyte-stimulating hormone. The compound is supplied as an acetate salt in aqueous solution for injection. In reference literature it is indexed under both the code and the generic name, a dual listing that can complicate database searches.
Early work on melanocortin analogs in the 1980s and 1990s produced peptides intended to influence pigmentation and appetite. One of these, melanotan II, was observed to affect sexual desire as an incidental finding in self-administration reports. Researchers then pursued analogs with altered receptor selectivity and improved handling characteristics, and PT-141 emerged from that program in the late 1990s. The development path moved from dermatology and metabolism toward a central nervous system application, a shift that shaped both trial designs and the eventual label.
Regulatory review of bremelanotide concluded in 2019 with approval in the United States for a defined indication in premenopausal women. The reviewed formulation is a single-use prefilled autoinjector given subcutaneously, and its label carries cardiovascular monitoring language tied to blood pressure changes recorded during trials. Availability outside the approving jurisdiction varies, and in several countries the compound remains unapproved or is handled as a prescription-only item. Compounded and research-grade material also circulates, and it differs from the reviewed product in purity, characterization, and chain of custody.
The melanocortin system comprises five G protein-coupled receptors, designated MC1 through MC5, that signal mainly through cyclic AMP accumulation. MC1R and MC2R are associated with pigmentation and adrenal steroid production, while MC3R and MC4R are expressed in the central nervous system and influence energy balance and behavior. MC5R appears in exocrine tissues. Natural agonists include alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone, and endogenous antagonists such as agouti-related protein modulate the same sites. This receptor family provides the framework within which bremelanotide activity is described.
Bremelanotide acts as an agonist at several melanocortin receptors, with the strongest reported activity at MC4R and measurable activity at MC1R and MC3R. Because MC4R is expressed in hypothalamic and limbic circuits, the proposed mechanism links receptor activation to modulation of central pathways involved in desire rather than to direct effects on peripheral genital tissue. The precise downstream steps remain incompletely characterized, and evidence for the involvement of specific neurotransmitters is suggestive rather than settled. Nausea and blood pressure elevation reported during trials are consistent with melanocortin signaling outside the intended target circuit.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H68N14O10 | Cyclic heptapeptide core |
| Molecular weight | 1025.2 g/mol | Calculated for the free base |
| CAS registry number | 189691-06-3 | Free base; the acetate salt has a separate entry |
| Solubility class | Water-soluble | Freely soluble in aqueous media near neutral pH |
| Typical storage | 2 to 8 °C | Protect from light; avoid repeated freeze-thaw cycles |
PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide developed as a melanocortin receptor agonist. The peptide contains seven amino acids with an internal lactam bridge that constrains the backbone into a stable ring. Cyclisation of this kind improves resistance to enzymatic degradation relative to linear analogues. The compound was first explored for effects on melanin production, because several melanocortin receptors influence pigmentation. Its later association with sexual desire emerged from observations made during that early work, and the molecule became the subject of a separate development programme.
Bremelanotide is a moderately large peptide with a molecular mass near 1025 daltons. In lyophilised form it appears as a white to off-white powder and is freely soluble in water and other polar solvents. The intact lactam ring is essential for receptor affinity, while linearised fragments bind far more weakly. Solutions are sensitive to extremes of pH and to prolonged exposure to light and heat, so handling typically involves buffered conditions and cold storage. Its short plasma half-life reflects rapid distribution and clearance rather than chemical breakdown inside the vial.
Clinical programmes in this area have relied mainly on randomised, double-blind, placebo-controlled designs in premenopausal women. Primary endpoints usually combine a validated questionnaire covering desire domains with counts of satisfying sexual events and a separate measure of distress. Reported outcomes show statistically significant but modest average improvement over placebo, with wide individual variation. Adverse events such as nausea, flushing, and headache occur frequently and can limit tolerability. Whether short-term trial gains translate into lasting change for most users is an open question.
Evidence outside the studied population is sparse. Trials have concentrated on premenopausal women with a defined diagnosis, and data for postmenopausal women, men, and people taking interacting medications remain limited. Non-prescription use of the peptide for comparable goals is widespread but is not supported by published controlled data. Observed changes in blood pressure have drawn attention to cardiovascular monitoring during use. The literature generally frames the compound as a targeted receptor agonist rather than a general libido enhancer, and basic questions about mechanism and long-term safety are unresolved.
Outside the approved product, bremelanotide circulates as a research chemical sold by peptide vendors, often labelled PT-141. Such material is not manufactured under pharmaceutical quality standards, and independent testing has repeatedly found content that differs from the label. Analytical certificates supplied with a purchase are not strong evidence of purity because they are usually generated by the seller. Online discussion tends to blur the distinction between the approved drug and unregulated powder, which complicates interpretation of reported experiences.
PT-141 is the original development code for bremelanotide, a synthetic peptide first studied as a potential tanning and sexual-response agent in the 1990s. Researchers at a small American biotechnology firm designed it as a shortened analogue of melanotan II, which itself came from work on alpha-melanocyte-stimulating hormone. Early screening focused on pigmentation, but behavioural observations in animal models redirected attention toward sexual motivation. That shift made PT-141 one of the first melanocortin compounds investigated specifically for effects on desire rather than on skin colour.
Clinical development proceeded through two routes of administration. An intranasal formulation advanced first, but variable absorption and tolerability problems led to a switch to subcutaneous injection. The United States Food and Drug Administration approved the subcutaneous product in 2019 for hypoactive sexual desire disorder in premenopausal women. Marketing rights subsequently changed hands, and commercial availability has fluctuated since approval. Use in men, in postmenopausal women, and in combination with other agents remains outside the approved label.
Strassman argues that the more positive of the "external entities" encountered in DMT experiences should be understood as analogous to certain forms of angels: The medieval Jewish philosophers whom I rely upon for understanding the Hebrew Bible text and its concept of prophecy portray angels as God's intermediaries. That is, they perform a certain function for God. Within the context of my DMT research, I believe that the beings that volunteers see could be conceived of as angelic – that is, previously invisible, incorporeal spiritual forces that are engarbed or enclothed in a particular form – determined by the psychological and spiritual development of the volunteers – bringing a particular message or experience to that volunteer. Strassman's experimental participants also note that some other entities can subjectively resemble creatures more like insects and aliens. As a result, Strassman writes these experiences among his experimental participants "also left me feeling confused and concerned about where the spirit molecule was leading us. It was at this point that I began to wonder if I was getting in over my head with this research." Hallucinations of strange creatures had been reported by Stephen Szára in a 1958 study in psychotic patients, in which he described how one of his subjects under the influence of DMT had experienced "strange creatures, dwarves or something" at the beginning of a DMT trip.
Narrated by actress Nicola Duffett, directed by Gary Johnstone, produced by Paul Wilmshurst 18 September Coral Grief, 50 million years ago, northern Italy was under water; David Bellwood of James Cook University; David Barnes of the Australian Institute of Marine Science; biologist Garry Russ; the Florida Reef and Craig Quirolo; a 1970 episode of Four Corners (Australian TV program); Peter Moran and Sea star wasting disease; Peter Isdale and Bette Willis; biologist Angel Alcala of Silliman University, who was Secretary of Environment and Natural Resources from 1992–95; Peter Harrison of the National Marine Science Centre, Australia; geochemist Michael Gagan of the Australian National University.
Certificate of Merit (1987) from the Indian Chemical Society for the best paper presentation, at the Convention of Chemists, 1987 2. Special Award and Citation (1988) of the Syndicate of Calicut University, Kerala, India for outstanding research contributions during 1985-1988 3. Swarnajayanti Research Grant (2001), Special research grant to outstanding young researchers by DST, Govt. India 4. Ramanna Fellow, DST (2007) 5. Adjunct Professor, Material Science Programme, IIT, Kanpur 6. Dean, Chemical Sciences, Academy of Scientific and Innovative Research (AcSIR) 7. A. V. Rama Rao Foundation Award Lecture of JNCASR, Bangalore (2012) 8. R. A. Mashelkar Endowment, NCL Pune (2012) 9. Chair on Nanoscience and Nanotechnology, Centre for Nanoscience and Nanotechnology, Mahatma Gandhi University, Kottayam, Kerala, 2013 10. Prof. K. K. M. Yusuff Endowment, Cochin University of Science and Technology, 2013 11. CHEMCON distinguished speaker award, 2016. 12. ISCB-2017 Award given by Indian Society of Chemists and Biologists. Academy Fellowships 1. Fellow, Indian Academy of Sciences, Bangalore (2006) 2. Fellow, National Academy of Sciences, Allahabad, India (2011) 3. Fellow, Indian National Science Academy, New Delhi (2012) 4. Honorary Fellow, Kerala Academy of Sciences (2013) 5. Fellow, Royal Society of Chemistry, London (2014) 6. Fellow, The World Academy of Science (2015) Research Fellowships
Sources: en.wikipedia.org
=== Americas === Brazil introduced universal BCG immunization in 1967–1968, and the practice continues to this day. According to Brazilian law, BCG is also given to people who live together with patients with leprosy. Canadian Indigenous communities receive the BCG vaccine, and in the province of Quebec the vaccine was offered to children until the mid-1970s. Most countries in Central and South America have universal BCG immunizations, as does Mexico. The United States has never used mass immunization of BCG due to the rarity of tuberculosis in the US, relying instead on the detection and treatment of latent tuberculosis.
CaMKII has multiple modes of activation to cause the incorporation of AMPA receptors into the perisynaptic membrane. CAMKII enzyme is eventually responsible for the development of the actin cytoskeleton of neuronal cells and, eventually, for the dendrite and axon development (synaptic plasticity). The first is direct phosphorylation of synaptic-associated protein 97 (SAP97), a scaffolding protein. First, SAP-97 and Myosin-VI, a motor protein, are bound as a complex to the C-terminus of AMPARs. Following phosphorylation by CaMKII, the complex moves into the perisynaptic membrane. The second mode of activation is through the MAPK pathway. CaMKII activates the Ras proteins, which go on to activate p42/44 MAPK, which drives AMPAR insertion directly into the perisynaptic membrane.
== Etymology == The term "botany" comes from the Ancient Greek word botanē (βοτάνη) meaning "pasture", "herbs" "grass", or "fodder"; Botanē is in turn derived from boskein (Greek: βόσκειν), "to feed" or "to graze". Traditionally, botany has also included the study of fungi and algae by mycologists and phycologists respectively, with the study of these three groups of organisms remaining within the sphere of interest of the International Botanical Congress.
Sources: en.wikipedia.org
=== Cycloelimination reaction === This reaction occurs mainly in four-membered cyclic molecules. Once ionized, it produces a distonic ion and then further fragments to yield an ethene radical ion and a neutral ethene molecule.
== Medical uses == Penbutolol is used to treat mild to moderate high blood pressure. Like other beta blockers it is not a first line treatment for this indication. It should not be used or only used with caution in people with heart failure and people with asthma. It may mask signs of low blood sugar in people with diabetes and it may mask signs of hyperthyroidism. Animal studies showed some signs of potential trouble for women who are pregnant, and it has not been tested in women who are pregnant. It is not known if penbutolol is secreted in breast milk.
== Sources == This article incorporates text from a free content work. Licensed under Creative Commons Attribution (license statement/permission). Text taken from Late Professor P N Saxena: A teacher of excellence, Rahman, SZ; Khan, RA (Nov 2010), J Pharmacol Pharmacother.
=== 1925: White Castle Official House Organ, success, expansion and imitators === The company also began publishing its own internal employee magazine, the White Castle Official House Organ, circa November 1925 (it was originally named The Hot Hamburger). The bulk of the material was contributed by company personnel and consisted mostly of letters and photographs of workers, promotional announcements, 25-year milestones, retirements, and similar items of interest arranged by geographic area. "Employees could... read about the progress and innovations made by those in other areas which made everyone aware of the entire system's direction and condition." The White Castle Official House Organ was published quarterly at least through the early 1980s, and at some point was renamed The Slider Times. The Ohio History Connection houses an extensive archive of White Castle System, Inc. records from 1921 to 1991, including issues dating from 1927 to 1970 of the White Castle Official House Organ.
Sources: en.wikipedia.org
PT-141 was the internal development code assigned to bremelanotide during preclinical research. Reference sources sometimes index the peptide under the code rather than the generic name. The two terms describe the same molecule.
They are related but distinct cyclic peptides. Melanotan II is an earlier and less selective melanocortin analog. Bremelanotide was developed later with a narrower receptor profile and a defined clinical application.
The reviewed product is given by subcutaneous injection using a single-use autoinjector. Administration occurs under prescription supervision. The device delivers one fixed amount per use rather than a measured or adjustable quantity.
Reported activity is highest at MC4R, with lower potency at MC1R and MC3R. The MC4R interaction is generally treated as the most relevant to its central effects. Selectivity is not absolute, and activity across the family is dose-dependent.